Where do I find Rubraca support and resources? | Rubraca® (rucaparib) tablets
Home
What else should I know about Rubraca?
Where do I find Rubraca support and resources?

Resources for men taking Rubraca

Brochure image
Rubraca Brochure
This informative brochure can help answer some questions you may have about Rubraca once you’ve started treatment.

Organizations supporting men, family members, and caregivers impacted by BRCA+ metastatic castration-resistant prostate cancer

FORCE logo Male Care logo MHN logo PCF logo PCRI logo PCEC logo PHEN logo UsToo logo Zero logo

Please note: All logos are registered trademarks of their specific organizations.

Clovis Oncology is not affiliated with and does not endorse any of the listed organizations. The information and resources available on these sites reflect the opinions and recommendations of the individual organizations only.

Glossary

Antiemetics/antinausea medication: drugs taken to prevent or treat nausea and vomiting.

Blood-based biopsy: also called a liquid biopsy. A type of biopsy done on a blood sample to look for either DNA or cancer cells from a tumor that are circulating in the blood. 

BRCA: stands for breast cancer susceptibility gene.

BRCA+: term used to describe a patient who has a BRCA gene mutation. 
    
BRCA gene mutation: a break in the BRCA1 or BRCA2 gene that normally aids in repairing cell DNA damage; BRCA gene mutations can be inherited (germline) or acquired spontaneously (somatic).

Castration-resistant prostate cancer: prostate cancer that no longer responds to drug or surgical treatments to lower testosterone.

Chemotherapy: a type of cancer treatment that uses drugs to eliminate cancer cells. Rubraca is approved for patients following the use of a taxane-based chemotherapy which is commonly given through a slow injection into a vein.

Clinical study: research that is designed to test new medical approaches, such as new medicines, and find out if they work and are safe for people.

DNA (deoxyribonucleic acid): molecules that tell your cells how to survive and grow.

Genes: a set of coded instructions in cells for making new proteins and controlling how cells behave.

Germline BRCA mutation: also called an inherited mutation, meaning the gene mutation is passed down from parent to child. Germline mutations are present in every cell in the body, not just in the tumor cells.

mCRPC (metastatic castration-resistant prostate cancer): prostate cancer that has spread to other parts of the body and that no longer responds to drug or surgical treatments to lower testosterone. 

Metastatic prostate cancer: prostate cancer that has spread to other parts of the body.

Mutation: a change in the DNA sequence.

PARP inhibitor (PARPi) (poly (ADP-ribose) polymerase inhibitor): medication that blocks PARP, a protein that helps repair DNA when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors may also impact other cells and tissues.

Response: therapeutic effect of treatment.

Side effect: a problem that may occur when treatment affects healthy tissues or organs.

Somatic BRCA mutation: also called an acquired mutation, meaning the gene mutation is not passed down from parent to child, but occurs randomly and can develop at any time. Somatic mutations are only present in the tumor cells.

INDICATION

Read Full ISI

What is Rubraca used for?

Rubraca® (rucaparib) tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):

  • that has spread to other parts of the body, and
  • has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer.

Rubraca was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit of Rubraca. Your healthcare provider will perform a test to make sure Rubraca is right for you.

It is not known if Rubraca is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

What Warnings should I know about Rubraca?

Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

You should not use Rubraca if you are a male with a female partner who is pregnant or able to become pregnant. Effective birth control should be used during treatment and for 3 months after the last dose of Rubraca. Do not donate sperm during use and for 3 months after the last dose of Rubraca.

What other important information should I know about Rubraca?

Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

Avoid spending time in sunlight while on Rubraca since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the side effects of Rubraca?

The most common side effects for men in Rubraca clinical studies were weakness/fatigue, nausea, decreased red blood cell count, changes in liver function tests, decreased appetite, constipation, rash, decreased platelet count, vomiting, and diarrhea.

What other medications might interact with Rubraca?

Rubraca can increase the amounts of other medications you may be taking which can increase the risk of side effects. Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information, including Patient Information, for additional Important Safety Information.

INDICATION

Read Full ISI

What is Rubraca used for?

Rubraca® (rucaparib) tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):

  • that has spread to other parts of the body, and
  • has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer.

Rubraca was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit of Rubraca. Your healthcare provider will perform a test to make sure Rubraca is right for you.

It is not known if Rubraca is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

What Warnings should I know about Rubraca?

Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

You should not use Rubraca if you are a male with a female partner who is pregnant or able to become pregnant. Effective birth control should be used during treatment and for 3 months after the last dose of Rubraca. Do not donate sperm during use and for 3 months after the last dose of Rubraca.

What other important information should I know about Rubraca?

Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

Avoid spending time in sunlight while on Rubraca since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the side effects of Rubraca?

The most common side effects for men in Rubraca clinical studies were weakness/fatigue, nausea, decreased red blood cell count, changes in liver function tests, decreased appetite, constipation, rash, decreased platelet count, vomiting, and diarrhea.

What other medications might interact with Rubraca?

Rubraca can increase the amounts of other medications you may be taking which can increase the risk of side effects. Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information, including Patient Information, for additional Important Safety Information.